WGS
GeneDx Holdings Corp.
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Sell
-22/100
Last price
71.25
▼ 5.02 (6.58%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
75.51
Prev close
76.27
Day high
79.68
Day low
70.24
Volume
816.89K
Market cap
$2.13B
P/E (TTM)
—
52W range
32.21 – 170.87
Day trading desk
Gap from prior close
-0.99%
Prior close 76.27
VWAP
71.87
-0.85% from price
Relative volume
1.77×
Unusually busy
Session range
13.44%
70.24 – 79.68
Position in range
11%
Near session low
ATR (14D)
7.00
9.82% of price
Prior day high
77.20
PDH
Prior day low
72.04
PDL
Bid / ask spread
—
Quote not published
Session volume
1.28M
Avg 725.37K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-5.63%
-7.6%
1M
-16.83%
-18.0%
3M
+8.99%
+4.5%
6M
+6.92%
-11.3%
YTD
-45.01%
-59.3%
1Y
-39.52%
-55.9%
3Y
+1,864.84%
+1,782.6%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on WGS open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
+2.30M
Net buying
Buy transactions
20
2.33M shares
Sell transactions
10
27.42K shares
Net transactions
+30
Buys less sells
Sell : buy shares
0.0 : 1
Mixed
Insider-held shares
2.30M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Sep 9, 26 | STUELAND KATHERINE Chief Executive Officer |
SELL | 3.69K | $310.93K | Direct |
| Sep 9, 26 | FEELEY KEVIN Chief Financial Officer |
SELL | 1.28K | $108.22K | Direct |
| Sep 9, 26 | STUELAND KATHERINE Chief Executive Officer |
— | 6.55K | — | Direct |
| Sep 9, 26 | FEELEY KEVIN Chief Financial Officer |
— | 2.46K | — | Direct |
| Sep 1, 26 | FEELEY KEVIN Chief Financial Officer |
SELL | 372 | $31.19K | Direct |
| Sep 1, 26 | FEELEY KEVIN Chief Financial Officer |
— | 717 | — | Direct |
| Jun 18, 26 | PFENNIGER RICHARD C JR Director |
— | 3.58K | — | Direct |
| Jun 18, 26 | RUCH JOSHUA Director |
— | 3.58K | — | Direct |
| Jun 18, 26 | MEISTER KEITH A Director and Beneficial Owner of more than 10% of a Class of Security |
— | 3.58K | — | Direct |
| Jun 18, 26 | RYAN JASON C Director |
— | 3.58K | — | Direct |
| Jun 18, 26 | CASDIN ELI Director and Beneficial Owner of more than 10% of a Class of Security |
— | 3.58K | — | Direct |
| Jun 18, 26 | LEPROUST EMILY M Director |
— | 3.58K | — | Direct |
| Jun 16, 26 | STUELAND KATHERINE Chief Executive Officer |
SELL | 10.50K | $638.10K | Direct |
| Jun 16, 26 | FEELEY KEVIN Chief Financial Officer |
SELL | 3.73K | $226.60K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
CASDIN CAPITAL, LLC |
Beneficial Owner of more than 10% of a Class of Security | — | Purchase |
CASDIN ELI |
Director and Beneficial Owner of more than 10% of a Class of Security | 4.08M | Conversion of Exercise of derivative security |
FEELEY KEVIN |
Chief Financial Officer | 41.48K | Sale |
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI |
Beneficial Owner of more than 10% of a Class of Security | 2.72M | Sale |
LEPROUST EMILY M |
Director | 24.85K | Conversion of Exercise of derivative security |
MEISTER KEITH A |
Director and Beneficial Owner of more than 10% of a Class of Security | 5.14M | Conversion of Exercise of derivative security |
PFENNIGER RICHARD C JR |
Director | 45.08K | Conversion of Exercise of derivative security |
RUCH JOSHUA |
Director | 189.57K | Conversion of Exercise of derivative security |
RYAN JASON C |
Director | 118.76K | Conversion of Exercise of derivative security |
STUELAND KATHERINE |
Chief Executive Officer | 107.23K | Sale |
Fundamentals
Market cap$2.13B
Enterprise value$2.17B
Revenue (TTM)$454.43M
Gross profit$315.30M
EBITDA$-33.70M
Net income$-106.36M
EPS (TTM)$-3.63
Free cash flow$-47.50M
Total cash$132.55M
Total debt$167.40M
Book value / share$8.19
Shares outstanding29.82M
Float20.44M
Short % of float37.77%
Dividend yield0.00%
Beta (5Y)1.97
Valuation & profitability ratios
Trailing P/E—
Forward P/E59.67
PEG ratio—
Price / sales—
Price / book8.73
EV / revenue4.77
EV / EBITDA-64.34
Gross margin69.38%
Operating margin-15.21%
Profit margin-23.41%
Return on equity-40.80%
Return on assets-7.89%
Debt / equity68.55
Current ratio3.30
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $427.54M | $305.45M | $202.57M | $234.69M | +40.0% |
| Operating revenue | $416.67M | $302.16M | $195.65M | $227.33M | +37.9% |
| Cost of revenue | $129.37M | $111.05M | $112.56M | $261.44M | +16.5% |
| Gross profit | $298.17M | $194.40M | $90.01M | -$26.75M | +53.4% |
| Research & development | $72.03M | $45.72M | $58.27M | $86.20M | +57.5% |
| Selling, general & admin | $239.22M | $171.89M | $199.98M | $338.24M | +39.2% |
| Total operating expense | $311.25M | $217.61M | $260.20M | $430.76M | +43.0% |
| Operating income | -$13.08M | -$23.21M | -$170.19M | -$457.51M | +43.7% |
| Net interest income | -$2.54M | -$3.03M | $1.11M | -$666.00K | +16.3% |
| Pre-tax income | -$21.14M | -$52.63M | -$176.69M | -$598.03M | +59.8% |
| Tax provision | -$116.00K | -$343.00K | -$926.00K | -$49.05M | +66.2% |
| Net income | -$21.02M | -$52.29M | -$175.77M | -$548.98M | +59.8% |
| Net income to common | -$21.02M | -$52.29M | -$175.77M | -$548.98M | +59.8% |
| Basic EPS | -0.73 | -1.94 | -7.23 | -53.79 | +62.4% |
| Diluted EPS | -0.73 | -1.94 | -7.23 | -53.79 | +62.4% |
| EBIT | -$13.08M | -$23.21M | -$170.19M | -$457.51M | +43.7% |
| EBITDA | $12.15M | -$1.26M | -$136.46M | -$398.20M | +1,064.0% |
| Basic shares | 28.64M | 26.89M | 24.31M | 10.24M | +6.5% |
| Diluted shares | 28.64M | 26.89M | 24.31M | 10.24M | +6.5% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $105.00M | $85.21M | $99.68M | $123.93M | +23.2% |
| Cash & short-term investments | $171.28M | $141.19M | $130.15M | $123.93M | +21.3% |
| Accounts receivable | $74.37M | $37.63M | $32.37M | $42.63M | +97.6% |
| Inventory | $13.95M | $10.65M | $8.78M | $13.66M | +31.0% |
| Total current assets | $268.29M | $197.97M | $182.34M | $212.62M | +35.5% |
| Property, plant & equipment | $69.11M | $58.51M | $59.38M | $84.28M | +18.1% |
| Goodwill & intangibles | $182.00M | $158.60M | $172.63M | $186.65M | +14.8% |
| Total assets | $523.71M | $419.38M | $418.76M | $490.94M | +24.9% |
| Total current liabilities | $108.91M | $54.82M | $58.82M | $144.30M | +98.7% |
| Current debt | $4.54M | $1.21M | $497.00K | $4.75M | +275.1% |
| Long-term debt | $48.18M | $51.91M | $52.69M | $6.25M | -7.2% |
| Total debt | $113.17M | $117.38M | $119.27M | $77.13M | -3.6% |
| Total liabilities | $215.53M | $174.13M | $190.74M | $237.24M | +23.8% |
| Retained earnings | -$1.37B | -$1.35B | -$1.30B | -$1.12B | -1.6% |
| Shareholder equity | $308.18M | $245.25M | $228.02M | $253.71M | +25.7% |
| Working capital | $159.38M | $143.15M | $123.52M | $68.33M | +11.3% |
| Net tangible assets | $126.18M | $86.65M | $55.39M | $67.06M | +45.6% |
| Shares issued | 29.25M | 28.02M | 25.98M | 11.77M | +4.4% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$21.02M | -$52.29M | -$175.77M | -$548.98M | +59.8% |
| Depreciation & amortisation | $25.22M | $21.95M | $33.73M | $59.31M | +14.9% |
| Stock-based compensation | $32.16M | $9.14M | -$326.00K | $41.98M | +252.0% |
| Change in working capital | -$15.60M | -$24.75M | -$38.24M | $33.88M | +37.0% |
| Operating cash flow | $33.28M | -$28.50M | -$180.15M | -$319.15M | +216.8% |
| Capital expenditure | -$19.02M | -$5.49M | -$5.71M | -$14.32M | -246.3% |
| Investing cash flow | -$61.52M | -$30.13M | -$43.73M | -$141.33M | -104.2% |
| Financing cash flow | $48.02M | $44.16M | $186.24M | $197.31M | +8.7% |
| Free cash flow | $14.26M | -$33.99M | -$185.86M | -$333.48M | +142.0% |
| End cash position | $105.99M | $86.20M | $100.67M | $138.30M | +23.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $114.44M | $102.25M | $120.99M | $116.74M | $102.69M | — | +11.9% |
| Operating revenue | $111.89M | $101.30M | $117.29M | $113.52M | $100.10M | — | +10.5% |
| Cost of revenue | $36.20M | $34.04M | $36.72M | $32.22M | $31.79M | — | +6.3% |
| Gross profit | $78.24M | $68.21M | $84.27M | $84.53M | $70.90M | — | +14.7% |
| Research & development | $19.66M | $19.80M | $24.54M | $19.83M | $15.08M | — | -0.7% |
| Selling, general & admin | $72.73M | $74.59M | $76.13M | $67.19M | $46.10M | — | -2.5% |
| Total operating expense | $93.48M | $94.39M | $98.50M | $87.78M | $61.87M | — | -1.0% |
| Operating income | -$15.24M | -$26.18M | -$14.23M | -$3.25M | $9.03M | — | +41.8% |
| Net interest income | -$1.19M | -$717.00K | -$520.00K | -$562.00K | -$817.00K | — | -65.3% |
| Pre-tax income | -$18.26M | -$62.42M | -$18.23M | -$7.39M | $10.56M | — | +70.7% |
| Tax provision | -$518.00K | $897.00K | -$564.00K | $247.00K | -$246.00K | — | -157.7% |
| Net income | -$17.74M | -$63.32M | -$17.67M | -$7.63M | $10.81M | — | +72.0% |
| Net income to common | -$17.74M | -$63.32M | -$17.67M | -$7.63M | $10.81M | — | +72.0% |
| Basic EPS | -0.60 | -2.16 | — | -0.27 | 0.38 | -0.23 | +72.2% |
| Diluted EPS | -0.60 | -2.16 | — | -0.27 | 0.36 | -0.23 | +72.2% |
| EBIT | -$17.07M | -$61.70M | -$14.23M | -$3.25M | $11.38M | — | +72.3% |
| EBITDA | -$10.36M | -$54.89M | -$7.35M | $3.22M | $17.57M | — | +81.1% |
| Basic shares | 29.71M | 29.34M | — | 28.80M | 28.58M | 28.15M | +1.3% |
| Diluted shares | 29.71M | 29.34M | — | 28.80M | 29.75M | 28.15M | +1.3% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $60.32M | $93.92M | $105.00M | $95.97M | $74.12M | -35.8% |
| Cash & short-term investments | $132.55M | $170.69M | $171.28M | $155.08M | $134.56M | -22.3% |
| Accounts receivable | $83.61M | $76.93M | $74.37M | $60.94M | $48.03M | +8.7% |
| Inventory | $17.82M | $12.24M | $13.95M | $10.57M | $11.93M | +45.6% |
| Total current assets | $246.36M | $270.63M | $268.29M | $237.58M | $204.84M | -9.0% |
| Property, plant & equipment | $87.85M | $84.78M | $69.11M | $66.62M | $65.10M | +3.6% |
| Goodwill & intangibles | $142.99M | $146.61M | $182.00M | $185.38M | $189.62M | -2.5% |
| Total assets | $481.49M | $506.30M | $523.71M | $493.90M | $463.86M | -4.9% |
| Total current liabilities | $74.63M | $87.64M | $108.91M | $87.62M | $71.41M | -14.8% |
| Current debt | — | — | $4.54M | — | — | — |
| Long-term debt | $96.84M | $96.73M | $48.18M | $51.58M | $51.68M | +0.1% |
| Total debt | $167.40M | $168.19M | $113.17M | $113.16M | $114.39M | -0.5% |
| Total liabilities | $237.26M | $252.18M | $215.53M | $201.64M | $186.73M | -5.9% |
| Retained earnings | -$1.45B | -$1.44B | -$1.37B | -$1.36B | -$1.35B | -1.2% |
| Shareholder equity | $244.22M | $254.12M | $308.18M | $292.26M | $277.13M | -3.9% |
| Working capital | $171.73M | $182.99M | $159.38M | $149.96M | $133.43M | -6.2% |
| Net tangible assets | $101.23M | $107.51M | $126.18M | $106.88M | $87.52M | -5.8% |
| Shares issued | 29.80M | 29.67M | 29.25M | 28.89M | 28.71M | +0.5% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$17.74M | -$63.32M | -$17.67M | -$7.63M | $10.81M | +72.0% |
| Depreciation & amortisation | $6.71M | $6.81M | $6.88M | $6.47M | $6.19M | -1.4% |
| Stock-based compensation | $6.34M | $9.00M | $9.78M | $10.59M | $7.81M | -29.5% |
| Change in working capital | -$22.64M | -$23.16M | $262.00K | -$2.87M | -$16.34M | +2.3% |
| Operating cash flow | -$28.98M | -$32.41M | -$3.09M | $15.77M | $10.42M | +10.6% |
| Capital expenditure | -$10.11M | -$6.45M | -$4.35M | -$6.17M | -$2.37M | -56.7% |
| Investing cash flow | -$5.63M | -$17.25M | -$11.07M | -$4.69M | -$36.35M | +67.4% |
| Financing cash flow | $1.00M | $38.59M | $23.19M | $10.77M | $346.00K | -97.4% |
| Free cash flow | -$39.09M | -$38.86M | -$7.44M | $9.60M | $8.05M | -0.6% |
| End cash position | $61.31M | $94.92M | $105.99M | $96.96M | $75.11M | -35.4% |
Options analytics
Put / call volume
5.18
Put-heavy session
Put / call open interest
2.43
Positioning, not flow
Max pain
81.00
+13.3% from spot
ATM implied vol
108.3%
Nearest strike to spot
Skew (10% OTM)
-29.5%
Calls bid over puts
Call volume
85
Contracts, this expiry
Put volume
440
Contracts, this expiry
Heaviest call OI
106.00
50 contracts
Heaviest put OI
81.00
53 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.19 | 0.01 | +105.3% |
| Mar 2026 | -0.02 | -0.28 | -1,407.8% |
| Dec 2025 | 0.12 | 0.14 | +16.7% |
| Sep 2025 | 0.42 | 0.49 | +15.9% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | 0.07 | 7 | $122.93M | +5.3% |
| Next quarter | 0.32 | 7 | $142.64M | +17.9% |
| Current year | 0.13 | 7 | $481.84M | +12.7% |
| Next year | 1.20 | 7 | $598.96M | +24.3% |
Analyst targets & ownership
Mean target$93.50
High target$103.00
Low target$83.00
Implied upside31.22%
Analyst count8
ConsensusSTRONG BUY
Strong buy / Buy1 / 7
Hold0
Sell / Strong sell0 / 0
Held by insiders7.71%
Held by institutions107.60%
Institutions holding306
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
78.79
-9.57% from price
SMA 20
86.01
-16.84% from price
SMA 50
81.83
-12.60% from price
SMA 100
69.95
+1.86% from price
SMA 200
77.73
-7.99% from price
EMA 12
79.45
-10.32% from price
EMA 26
82.43
-13.56% from price
EMA 50
80.39
-11.36% from price
RSI (14)
37.5
Neutral
MACD (12,26,9)
-2.98
Hist -2.62
ATR (14)
7.00
9.78% of price
Realised vol 30D
68.3%
Annualised
Bollinger upper
105.88
20, 2σ
Bollinger lower
66.13
20, 2σ
50 / 200 cross
Golden
81.83 vs 77.73
Trend bias
Below 200
-7.99%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.42
More volatile than market
Correlation to SPY
0.22
Largely independent
Realised vol 30D
68.3%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-79.4%
Peak to trough
Max drawdown 5Y
-99.6%
Peak to trough
ATR 14
7.00
9.78% of price
Beta (reported)
1.97
5Y monthly, from filing
Short interest
Shares short
5.88M
Prior 6.29M
Change vs prior
-6.4%
Shorts covering
% of float
37.77%
Heavily shorted
% of shares out
19.73%
Against total outstanding
Days to cover
11.9
Crowded exit
Float
20.44M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 1, 26 | Guggenheim | MAINTAINED | Buy | Buy |
| Aug 4, 26 | Canaccord Genuity | MAINTAINED | Buy | Buy |
| Aug 4, 26 | BTIG | MAINTAINED | Buy | Buy |
| Jun 29, 26 | Guggenheim | MAINTAINED | Buy | Buy |
| Jun 23, 26 | Piper Sandler | MAINTAINED | Overweight | Overweight |
| May 5, 26 | Canaccord Genuity | MAINTAINED | Buy | Buy |
| May 5, 26 | Wells Fargo | MAINTAINED | Overweight | Overweight |
| May 5, 26 | Guggenheim | MAINTAINED | Buy | Buy |
| May 5, 26 | BTIG | MAINTAINED | Buy | Buy |
| Apr 20, 26 | Canaccord Genuity | MAINTAINED | Buy | Buy |
| Mar 30, 26 | Guggenheim | MAINTAINED | Buy | Buy |
| Feb 24, 26 | Piper Sandler | MAINTAINED | Overweight | Overweight |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split1:33
Split dateMay 4, 2023
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-08-03
Corporate Changes & Voting Matters
8-K · 2026-06-23
Corporate Changes & Voting Matters
8-K · 2026-06-16
Corporate Changes & Voting Matters
8-K · 2026-05-04
Proxy Statements
DEF 14A · 2026-04-30
Corporate Changes & Voting Matters
8-K · 2026-03-02
Offering Registrations
S-8 · 2026-02-23
Corporate Changes & Voting Matters
8-K · 2026-01-12
Headlines
GeneDx Introduces Easy Order at AAP 2026 to Simplify Genomic Testing in Everyday Pediatric Care
Business Wire · 5d ago
GeneDx Stock Is Down 30% In Last 1 Year, Can It Climb Again in 2027?
TIKR · 13d ago
GeneDx and Beren Therapeutics Launch NPC GenomeComplete to Improve Diagnosis of Niemann-Pick Disease Type C
Business Wire · 28d ago
3 Promising Genomics Stocks in the Spotlight in 2026
Zacks · 28d ago
GeneDx CEO Katherine Stueland Recognized as a 2026 Fierce 50 Honoree
Business Wire · 36d ago
Top Stock Picks for Week of August 24, 2026
Zacks · 43d ago
GeneDx Announces Transformative Study Supporting Hospital-Wide Adoption of Rapid Genomic Sequencing at Seattle Children’s
Business Wire · 44d ago
Can GENEDX HOLDINGS (WGS) Run Higher on Rising Earnings Estimates?
Zacks · 48d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.